Cardiff Oncology, Inc. (FRA:XE7C)
Germany
· Delayed Price · Currency is EUR 1.750
+0.076 (4.54%)
At close: Dec 4, 2025
Cardiff Oncology Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Cash & Equivalents | 10.14 | 51.47 | 21.66 | 16.35 | 11.94 | 130.98 | Upgrade
|
| Short-Term Investments | 50.46 | 40.28 | 53.17 | 88.92 | 128.88 | - | Upgrade
|
| Cash & Short-Term Investments | 60.59 | 91.75 | 74.82 | 105.27 | 140.82 | 130.98 | Upgrade
|
| Cash Growth | 5.07% | 22.62% | -28.92% | -25.25% | 7.51% | 1184.72% | Upgrade
|
| Accounts Receivable | 0.25 | 0.77 | 0.29 | 0.77 | 0.54 | 0.32 | Upgrade
|
| Other Receivables | - | 0.4 | 0.6 | - | - | - | Upgrade
|
| Receivables | 0.25 | 1.17 | 0.89 | 0.77 | 0.54 | 0.32 | Upgrade
|
| Prepaid Expenses | 0.96 | 2.14 | 1.7 | 5.25 | 4.77 | 2.06 | Upgrade
|
| Total Current Assets | 61.8 | 95.05 | 77.41 | 111.28 | 146.13 | 133.36 | Upgrade
|
| Property, Plant & Equipment | 1.43 | 2.07 | 2.95 | 3.52 | 3.18 | 0.97 | Upgrade
|
| Other Long-Term Assets | 0.55 | 0.07 | 1.28 | 1.39 | 0.24 | 0.4 | Upgrade
|
| Total Assets | 63.78 | 97.19 | 81.64 | 116.19 | 149.54 | 134.73 | Upgrade
|
| Accounts Payable | 2.44 | 4.82 | 1.97 | 1.96 | 1.44 | 1.37 | Upgrade
|
| Accrued Expenses | 11.54 | 7.9 | 7.78 | 5.18 | 4.11 | 3.46 | Upgrade
|
| Current Portion of Leases | 0.73 | 0.71 | 0.69 | 0.68 | 0.55 | 0.86 | Upgrade
|
| Other Current Liabilities | - | - | - | - | 0.46 | 0.43 | Upgrade
|
| Total Current Liabilities | 14.71 | 13.43 | 10.44 | 7.81 | 6.56 | 6.12 | Upgrade
|
| Long-Term Leases | 0.28 | 0.81 | 1.46 | 2.04 | 2.57 | 0.01 | Upgrade
|
| Other Long-Term Liabilities | - | - | - | - | - | 0.44 | Upgrade
|
| Total Liabilities | 14.99 | 14.24 | 11.9 | 9.85 | 9.13 | 6.57 | Upgrade
|
| Common Stock | 0.01 | 0.01 | 0 | 0 | 0 | 0 | Upgrade
|
| Additional Paid-In Capital | 471.55 | 467.09 | 409.34 | 404.83 | 400.5 | 361.82 | Upgrade
|
| Retained Earnings | -422.81 | -384.18 | -339.54 | -298.1 | -259.81 | -231.5 | Upgrade
|
| Comprehensive Income & Other | 0.05 | 0.03 | -0.07 | -0.4 | -0.28 | -2.17 | Upgrade
|
| Total Common Equity | 48.79 | 82.95 | 69.74 | 106.34 | 140.42 | 128.16 | Upgrade
|
| Shareholders' Equity | 48.79 | 82.95 | 69.74 | 106.34 | 140.42 | 128.16 | Upgrade
|
| Total Liabilities & Equity | 63.78 | 97.19 | 81.64 | 116.19 | 149.54 | 134.73 | Upgrade
|
| Total Debt | 1.01 | 1.52 | 2.15 | 2.72 | 3.12 | 0.87 | Upgrade
|
| Net Cash (Debt) | 59.58 | 90.22 | 72.67 | 102.55 | 137.7 | 130.11 | Upgrade
|
| Net Cash Growth | 6.43% | 24.15% | -29.13% | -25.53% | 5.83% | 1436.34% | Upgrade
|
| Net Cash Per Share | 0.94 | 1.89 | 1.63 | 2.35 | 3.53 | 6.23 | Upgrade
|
| Filing Date Shares Outstanding | 67.36 | 66.52 | 44.68 | 44.68 | 43.31 | 37.05 | Upgrade
|
| Total Common Shares Outstanding | 67.1 | 66.52 | 44.68 | 44.68 | 41.96 | 36.78 | Upgrade
|
| Working Capital | 47.1 | 81.63 | 66.97 | 103.48 | 139.57 | 127.24 | Upgrade
|
| Book Value Per Share | 0.73 | 1.25 | 1.56 | 2.38 | 3.35 | 3.48 | Upgrade
|
| Tangible Book Value | 48.79 | 82.95 | 69.74 | 106.34 | 140.42 | 128.16 | Upgrade
|
| Tangible Book Value Per Share | 0.73 | 1.25 | 1.56 | 2.38 | 3.35 | 3.48 | Upgrade
|
| Machinery | 2.5 | 2.47 | 2.42 | 2.12 | 1.86 | 1.67 | Upgrade
|
| Leasehold Improvements | 2.57 | 2.57 | 2.57 | 2.56 | 1.96 | 1.96 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.